Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 31, 2010, Pages 13824-13829

  Van Tendeloo, Viggo F ^a   Van De Veldea, Ann ^a   Van Driesschea, Ann ^a   Coolsa, Nathalie ^a   Anguille, Sébastien ^a   Ladell, Kristin ^b   Gostick, Emma ^b   Vermeulen, Katrien ^a   Pieters, Katrien ^a   Nijs, Griet ^a   Stein, Barbara ^a   Smits, Evelien L ^a   Schroyens, Wilfried A ^a   Gadisseur, Alain P ^a   Vrelust, Inge ^a   Jorens, Philippe G ^a   Goossens, Herman ^a   De Vries, I Jolanda ^c   Price, David A ^b   Oji, Yusuke ^d   Oka, Yoshihiro ^d   Sugiyama, Haruo ^d   Berneman, Zwi N ^a   more..

^a UNIVERSITY OF ANTWERP   (Belgium)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Active specific immunotherapy; Cancer vaccine; Phase I clinical trial

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; TUMOR MARKER; WT1 PROTEIN; CANCER VACCINE; MESSENGER RNA; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CD8+ T LYMPHOCYTE; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; BIOSYNTHESIS; DENDRITIC CELL; GENETICS; IMMUNOLOGY; METABOLISM; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; INTERFERON-GAMMA; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; RNA, MESSENGER; VACCINATION; WT1 PROTEINS;

EID: 77956384935     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008051107     Document Type: Article

References (59)

1. Altekruse SF, et al. (eds). (2010) SEER Cancer Statistics Review, 1975-2007 (National Cancer Institute. Bethesda, MD).
2. Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062.
3. Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet 368:1894-1907.
4. Ravandi F, Burnett AK, Agura ED, Kantarjian HM (2007) Progress in the treatment of acute myeloid leukemia. Cancer 110:1900-1910.
5. Sekeres MA (2008) Treatment of older adults with acute myeloid leukemia: State of the art and current perspectives. Haematologica 93:1769-1772.
6. Löwenberg B (1995) Post-remission treatment of acute myelogenous leukemia. N Engl J Med 332:260-262.
7. Greiner J, Döhner H, SchmittM (2006) Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91:1653-1661.
8. Scheibenbogen C, et al. (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100:2132-2137.
9. Rusakiewicz S, Molldrem JJ (2006) Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 18:599-604.
10. Rezvani K, et al. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111:236-242.
11. Oka Y, et al. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101:13885-13890.
12. Keilholz U, et al. (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113:6541-6548.
13. Schmitt M, et al. (2008) RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111:1357-1365.
14. Van Tendeloo VF, et al. (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49-56.
15. Van Driessche A, et al. (2005) Antigen-specific cellular immunotherapy of leukemia. Leukemia 19:1863-1871.
16. Hsu FJ, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58.
17. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF (2009) Dendritic cell-based cancer gene therapy. Hum Gene Ther 20:1106-1118.
18. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29:372-383.
19. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915.
20. Bendandi M (2009) Idiotype vaccines for lymphoma: Proof-of-principles and clinical trial failures. Nat Rev Cancer 9:675-681.
21. Inoue K, et al. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079.
22. Menssen HD, et al. (1995) Presence ofWilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060-1067.
23. Inoue K, et al. (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412.
24. Yang L, Han Y, Suarez Saiz F, Saurez Saiz F, Minden MD (2007) A tumor suppressor and oncogene: The WT1 story. Leukemia 21:868-876.
25. Cilloni D, et al. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 27:5195-5201.
26. Yamagami T, et al. (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878-2884.
27. Greiner J, Bullinger L, Guinn BA, Döhner H, Schmitt M (2008) Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 14:7161-7166.
28. Nishida S, et al. (2006) AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107:3303-3312.
29. Hosen N, et al. (2007) The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 21:1783-1791.
30. Gao L, et al. (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198-2203.
31. Gao L, et al. (2003) Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75:1429-1436.
32. Xue SA, et al. (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106:3062-3067.
33. Cheever MA, et al. (2009) The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337.
34. Inoue K, et al. (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88:2267-2278.
35. Cilloni D, et al. (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121.
36. Trka J, et al. (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16:1381-1389.
37. Garg M, Moore H, Tobal K, Liu Yin JA (2003) Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123:49-59.
38. Lapillonne H, et al. (2006) High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515.
39. Cilloni D, et al. (2008) Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93:921-924.
40. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA (2006) NK cell activation by dendritic cell vaccine: A mechanism of action for clinical activity. Cancer Immunol Immunother 55:1122-1131.
41. Woo CY, Clay TM, Lyerly HK, Morse MA, Osada T (2006) Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines 5:55-65.
42. Cheson BD, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649.
43. Rezvani K, et al. (2005) T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization. Clin Cancer Res 11:8799-8807.
44. Melenhorst JJ, et al. (2009) High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 113:2238-2244.
45. Kyte JA, et al. (2007) T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 56:659-675.
46. Kyte JA, et al. (2009) Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 58:1609-1626.
47. Coulie PG, van der Bruggen P (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131-137.
48. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57:1559-1568.
49. Wolfl M, et al. (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110:201-210.
50. Bonehill A, et al. (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172:6649-6657.
51. Lee JJ, et al. (2004) Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 19:66-70.
52. Li L, et al. (2006) Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 28:855-861.
53. Roddie H, et al. (2006) Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 133:152-157.
54. Sakamoto Y, et al. (2009) WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med 219:169-176.
55. Ogawa H, et al. (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698-1704.
56. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H (2008) WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211-220.
57. Van Driessche A, et al. (2009) Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11:653-668.
58. Murthy V, Moiyadi A, Sawant R, Sarin R (2009) Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr Mol Med 9:725-731.
59. Oji Y, et al. (2009) WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 125:381-387.